Sugi Predict

Sugi Predict / Compounds / SCHEMBL10043855

SCHEMBL10043855

SCHEMBL10043855

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3cc(F)cc(F)c3)ccc1C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 1/20 0.43
▸ MAPK14 Q16539 12/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ RAF1 P04049 2/20 0.37
▸ MAPKAPK2 P49137 2/20 0.37
▸ MAPK13 O15264 1/20 0.37
▸ PDGFRA P16234 1/20 0.37
▸ MAPK12 P53778 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ MAPK11 Q15759 1/20 0.37
▸ BRAF P15056 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ LCK P06239 2/20 0.36
▸ KIT P10721 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ CCR2 P41597 1/20 0.36
▸ CCR5 P51681 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043869 0.93 GAA (0.45) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043666 0.93 SYK (0.49) SYKMAPK14RAF1MAPKAPK2MAPK13
SCHEMBL10043868 0.90 SYK (0.41) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043857 0.90 POLB (0.45) SYKMAPK14NPC1RAB9APOLB
SCHEMBL10043873 0.90 SYK (0.44) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043931 0.89 MAPK14 (0.47) SYKMAPK14RAF1MAPKAPK2MAPK13
SCHEMBL10043850 0.89 SYK (0.50) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043860 0.88 SYK (0.51) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043866 0.88 SYK (0.41) SYKMAPK14NPC1RAB9ARAF1
SCHEMBL10043851 0.88 PCTP (0.44) SYKMAPK14NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885NPC1 4095/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885NPC1 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.